8-K: Day One Reports Strong Q2 OJEMDA Revenue Growth

Day One Biopharmaceuticals announced robust second-quarter 2025 financial results, driven by significant growth in OJEMDA net product revenue and reaffirmed full-year guidance.

Summary

• OJEMDA net product revenue reached $33.6 million in Q2 2025, marking a 10% increase quarter-over-quarter and a 310% increase compared to Q2 2024.
• OJEMDA prescriptions exceeded 1,000 in Q2 2025, representing a 15% increase from Q1 2025 and a 346% increase from Q2 2024.
• The company achieved $113.1 million in OJEMDA net product revenue for the most recent 12-month period ended June 30, 2025.
• Full-year 2025 OJEMDA net product revenue guidance is set between $140 million and $150 million.
• Cash, cash equivalents, and short-term investments totaled $453.1 million as of June 30, 2025.
• Net loss for Q2 2025 was $30.3 million, compared to a net loss of $4.4 million in Q2 2024 (which included a $108.0 million gain from a priority review voucher sale).
• Research and development expenses decreased to $36.1 million in Q2 2025 from $92.1 million in Q2 2024, primarily due to a $55.0 million upfront payment in Q2 2024.
• Selling, general and administrative expenses decreased to $29.0 million in Q2 2025 from $30.2 million in Q2 2024.
• Patient enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial is on track to achieve completion in the first half of 2026.
• The company terminated its research collaboration and license agreement with Sprint Bioscience AB for the VRK1 program.

Sentiment

Score: 8

Explanation: The company reported strong commercial performance for its key product, OJEMDA, with significant revenue and prescription growth, and reaffirmed its full-year guidance. Pipeline progress is on track, and the company maintains a robust cash position, indicating strong operational execution and financial stability. While net loss increased, it was largely due to the absence of a one-time gain from the prior year, and underlying expenses decreased. The termination of the VRK1 program is a minor negative but reflects strategic focus.

Positives

• Strong OJEMDA net product revenue growth of $33.6 million in Q2 2025, a 10% quarter-over-quarter and 310% year-over-year increase.
• OJEMDA prescriptions surpassed 1,000 in Q2 2025, showing a 15% quarter-over-quarter and 346% year-over-year increase, indicating robust market uptake.
• Reaffirmed full-year 2025 OJEMDA net product revenue guidance of $140 million to $150 million, signaling confidence in continued commercial performance.
• Maintained a strong cash position of $453.1 million as of June 30, 2025, providing financial independence and flexibility for pipeline investment.
• Pivotal Phase 3 FIREFLY-2 clinical trial enrollment is on track for completion in the first half of 2026, advancing the pipeline for front-line pLGG.
• DAY301, the PTK7-targeted ADC, is actively enrolling patients in its Phase 1a portion, with the first dose cohort cleared in January 2025, indicating pipeline progress.
• Appointment of Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of extensive oncology R&D experience to the leadership team.
• Decreased research and development expenses (excluding a prior year one-time payment) and selling, general and administrative expenses, reflecting operational efficiency.

Negatives

• Net loss increased to $30.3 million in Q2 2025 from $4.4 million in Q2 2024, although the prior year benefited from a $108.0 million gain from the sale of a priority review voucher.
• Termination of the research collaboration and license agreement with Sprint Bioscience AB for the VRK1 program, indicating a strategic decision to discontinue development in that specific area.

Risks

• Ability to develop, obtain, and retain regulatory approval for or commercialize any product candidate.
• Ability to protect intellectual property.
• Potential impact of global business or macroeconomic conditions, including inflation, changing interest rates, cybersecurity incidents, significant political or regulatory developments, or changes in trade policy (e.g., tariffs).
• Shifting priorities within the U.S. Food and Drug Administration (FDA) and reduced funding to federal healthcare programs.
• Global regional conflicts.
• Sufficiency of cash, cash equivalents, and investments to fund operations.
• Risks and uncertainties associated with current and planned clinical trials.
• Uncertainty regarding the safety, efficacy, timing, and ability to complete clinical trials, release data results, and obtain regulatory approvals for tovorafenib and other candidates in development.
• Uncertainty regarding the ability of tovorafenib to treat pediatric low-grade glioma (pLGG) or related indications.
• Forward-looking statements may prove to be inaccurate, and such inaccuracy may be material.

Future Outlook

Day One Biopharmaceuticals expects full-year 2025 OJEMDA net product revenue to be between $140 million and $150 million. Patient enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial is on track to achieve completion in the first half of 2026. The company anticipates presenting 3-year follow-up data from the FIREFLY-1 clinical trial in the fourth quarter of 2025. An EMA regulatory decision for tovorafenib is expected in 2026.

Management Comments

• "We have strong momentum going into the second half of 2025. We continue to focus on our three core priorities: accelerating revenue growth with OJEMDA, advancing our pipeline, and pursuing value-driving portfolio expansion anchored in financial discipline."
• "With strong execution across the organization and a solid financial foundation, we're building a company that aims to deliver meaningful value to patients and to shareholders."

Industry Context

Day One Biopharmaceuticals operates in the highly specialized pediatric oncology market, focusing on targeted therapies for life-threatening diseases like pediatric low-grade glioma (pLGG). The company's lead product, OJEMDA, addresses a critical unmet need in a patient population where standard of care is often lacking and recurrence rates are high. The continued growth of OJEMDA revenue and prescriptions indicates successful market penetration and adoption within this niche, while pipeline advancements like DAY301 and the FIREFLY-2 trial position the company for broader impact in both pediatric and adult oncology, aligning with the industry trend towards precision medicine and targeted therapies.

Comparison to Industry Standards

• OJEMDA's 51% overall response rate (ORR) in the FIREFLY-1 trial for BRAF-altered pLGG patients demonstrates significant efficacy in a challenging pediatric cancer, positioning it favorably within the limited therapeutic landscape for this indication.
• The company's development of DAY301, a PTK7-targeted ADC, is positioned as a potential next-generation asset aiming to improve upon prior programs like Pfizer/AbbVie's cofetuzumab pelidotin, which showed ORRs of 27% in ovarian (Pt-resistant), 21% in TNBC, and 19% in NSCLC. DAY301 is designed for an optimized therapeutic index to achieve greater clinical efficacy.
• Day One's cash position of $453.1 million provides substantial financial independence, a strong competitive advantage compared to many smaller biopharmaceutical companies that frequently rely on capital markets for funding, enabling sustained investment in its pipeline.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reaffirmed guidance, pipeline progress, and solid financial position, indicating potential for long-term value creation.
• Patients: Positive impact through continued commercialization of OJEMDA for pediatric low-grade glioma and ongoing development of new therapies like DAY301, aiming to address unmet medical needs.
• Employees: Positive impact from continued company growth and strategic focus, potentially leading to stability and opportunities.
• Healthcare Providers (HCPs): Continued support and education for OJEMDA, aiming to establish it as a standard of care for r/r BRAF-altered pLGG.

Next Steps

• Accelerate revenue growth with OJEMDA.
• Advance the pipeline, including DAY301 and FIREFLY-2.
• Present 3-year follow-up data from the FIREFLY-1 clinical trial in Q4 2025.
• Complete patient enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial in 1H 2026.
• Await EMA regulatory decision for tovorafenib in 2026.
• Pursue value-driving portfolio expansion anchored in financial discipline.
• Drive depth of prescribing with current OJEMDA prescribers.
• Encourage non-user healthcare professionals (HCPs) to try OJEMDA in their next relapsed/refractory pediatric low-grade glioma (r/r pLGG) patient.
• Establish OJEMDA as standard of care in 2nd line r/r BRAF-altered pLGG.
• Support prescribers and patients to allow for optimal duration of treatment with OJEMDA.
• Advance two recommended dose levels for DAY301 to Phase 1b.
• Begin pediatric dose confirmation and efficacy assessment for DAY301 near/at the end of adult dose escalation.

Key Dates

Recommendation

Day One Biopharmaceuticals demonstrates robust commercial execution with OJEMDA, exceeding 1,000 prescriptions and achieving significant revenue growth, while maintaining a strong financial position. The reaffirmed full-year guidance and on-track pipeline advancements, including the pivotal FIREFLY-2 trial and the promising DAY301 ADC program, underscore the company's strategic focus and potential for sustained growth. The strong cash balance provides operational independence, mitigating near-term financing risks. Despite an increased net loss, it's primarily due to the absence of a prior-year one-time gain, with underlying operational expenses showing efficiency. This filing indicates strong fundamentals and positive momentum, making it an attractive investment.

Keywords

Biopharmaceuticals, Oncology, Pediatric Cancer, Low-Grade Glioma, BRAF, Tovorafenib, OJEMDA, Targeted Therapy, Clinical Trials, FDA Approval, DAY301, ADC, PTK7, Financial Results, Biotech, Rare Disease